IGM BIOSCIENCES INC. - COMMON STOCK

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

03 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

22 Jun 2023 07:58:50 By Nasdaq GlobeNewswire

IGM Announces Proposed Public Offering and Concurrent Private Placement

21 Jun 2023 17:17:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

02 Jun 2023 17:30:00 By Nasdaq GlobeNewswire

IGM Biosciences to Present at the Jefferies Healthcare Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

30 May 2023 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

12 May 2023 09:05:00 By Nasdaq GlobeNewswire

IGM Biosciences to Present at Two Upcoming Investor Conferences

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

19 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023

13 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

30 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023

27 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference

02 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors

17 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

09 Jan 2023 07:37:34 By Nasdaq GlobeNewswire

IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting

11 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference

01 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

IGM Biosciences to Present at Three Upcoming Investor Conferences

08 Nov 2022 07:00:02 By Nasdaq GlobeNewswire